Indications
Joenja is indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older and weighing 45 kg or more.
Composition
- Active substance
- leniolisib phosphate
- International name (INN)
- leniolisib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Joenja
- Active substance
- leniolisib phosphate
- ATC code
- L03AX22
- Therapeutic area
- Primary Immunodeficiency Diseases
- Marketing authorisation holder
- Pharming Technologies B.V.